The Mechanisms of Resistance in Breast Cancer
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.
George W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.
Clinical Pearls
The oncology community has discovered the mechanisms of resistance for several types of cancers, Sledge says. The next step is to figure out ways around them. A good example of this, Sledge notes is that when a patient becomes resistant to an aromatase inhibitor, mTOR inhibitors (such as everolimus) can overcome mechanisms of resistance. The oncology community now needs to apply known information to the entire breast cancer puzzle.
- The mechanisms of resistance for several types of cancers are known
- When a patient becomes resistant to an aromatase inhibitor, mTOR inhibitors can overcome mechanisms of resistance
- The next step, Sledge says, is to apply known information to the breast cancer puzzle
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
